Lenvatol 10mg Capsule contains Lenvatinib, a potent multi-kinase inhibitor used primarily in the treatment of various cancers, including differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma. Lenvatinib exerts its therapeutic effects by selectively inhibiting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT signaling pathways, thereby impeding tumor angiogenesis and proliferation. Administered orally, Lenvatol is indicated for patients with progressive, locally advanced, or metastatic disease who are refractory to radioactive iodine therapy or other standard treatments. The recommended dosage and administration should be individualized based on patient tolerance and clinical response, with close monitoring for adverse effects such as hypertension, proteinuria, fatigue, diarrhea, and hepatotoxicity. Regular assessment of blood pressure, liver function tests, and renal function is advised during therapy. Lenvatol should be used under strict medical supervision, considering potential drug interactions and contraindications. Patient adherence to prescribed dosing and follow-up schedules is essential to optimize therapeutic outcomes and minimize risks. This medication represents a significant advancement in targeted cancer therapy, offering improved progression-free survival in selected patient populations.